8-K: Indivior Terminates Reckitt Benckiser Supply Deal

Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited have agreed to accelerate the termination of their Copacker Supply Agreement for SUBOXONE and SUBUTEX Tablets to January 15, 2027.

Summary

• Indivior UK Limited (Indivior) and Reckitt Benckiser Healthcare (UK) Limited (RB) have entered into a Deed of Variation and Termination for their Copacker Supply Agreement.
• The agreement, originally dated December 23, 2014, and amended on March 29, 2019, involved RB manufacturing SUBOXONE Tablets and SUBUTEX Tablets for Indivior.
• The termination date of the Copacker Supply Agreement has been accelerated to January 15, 2027.
• Indivior has secured a new supplier, and the agreement with this new supplier is not expected to be material to Indivior Pharmaceuticals, Inc.
• Indivior will pay RB certain costs related to the termination, including costs for ordering lower volumes, asset disposal, depreciation recovery, redundancy, incentives, and potential third-party costs.
• These aggregate costs are fixed or capped and are not expected to be material to Indivior Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral development, as the termination of a supply agreement is a standard operational adjustment, with no immediate material financial impact indicated.

Positives

• Indivior has proactively identified a new supplier, ensuring continuity of manufacturing for its products.
• The costs associated with the termination are fixed or capped, providing cost certainty for Indivior.
• The financial impact of the termination and associated costs are not expected to be material to Indivior Pharmaceuticals, Inc.

Negatives

• The termination of a long-standing supply agreement may introduce some operational adjustments and transition risks.
• Indivior will incur certain costs to RB related to the accelerated termination, including costs for lower volume orders and other expenses.

Risks

• Potential disruption during the transition to a new manufacturing supplier.
• Unforeseen costs or complexities arising from the validation of the new supplier's manufacturing process.
• Any issues with the new supplier's ability to meet production demands or quality standards.

Future Outlook

Indivior has secured a new supplier, and the agreement with this new supplier is not expected to be material to Indivior Pharmaceuticals, Inc. The company will incur certain fixed or capped costs related to the termination of the current agreement.

Industry Context

StockSavvy.ai notes that the pharmaceutical industry frequently involves complex supply chain management and manufacturing agreements. The termination and replacement of such agreements are common as companies optimize operations, seek cost efficiencies, or adapt to changing market dynamics. This action by Indivior appears to be a standard operational adjustment.

Stakeholder Impact

• Shareholders: Minimal direct impact expected due to the stated non-material financial implications and proactive supplier replacement.
• Employees: Potential for some internal resource reallocation during the transition, but no significant impact indicated.
• Customers: No expected disruption to the supply of SUBOXONE Tablets and SUBUTEX Tablets.
• Suppliers: A change in manufacturing partner for Indivior, with Reckitt Benckiser Healthcare (UK) Limited ceasing production for Indivior.

Next Steps

• Transition manufacturing operations to the new identified supplier.
• Complete the termination of the Copacker Supply Agreement with Reckitt Benckiser Healthcare (UK) Limited by January 15, 2027.
• Finalize payments for costs associated with the termination as per the Deed of Variation and Termination.

Key Dates

Keywords

Supply Agreement, Manufacturing, Pharmaceuticals, Termination, Copacker, Suboxone, Subutex